Compare CTM & CYPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTM | CYPH |
|---|---|---|
| Founded | 2019 | 2011 |
| Country | United States | United States |
| Employees | N/A | 6 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.1M | 73.4M |
| IPO Year | 2022 | N/A |
| Metric | CTM | CYPH |
|---|---|---|
| Price | $0.84 | $1.18 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.5M | ★ 4.5M |
| Earning Date | 05-08-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 83.33 | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $52,866,001.00 | N/A |
| Revenue This Year | $20.36 | N/A |
| Revenue Next Year | $6.37 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 18.10 | N/A |
| 52 Week Low | $0.48 | $0.50 |
| 52 Week High | $1.56 | $3.70 |
| Indicator | CTM | CYPH |
|---|---|---|
| Relative Strength Index (RSI) | 67.69 | 55.57 |
| Support Level | $0.79 | $0.88 |
| Resistance Level | $0.99 | $1.30 |
| Average True Range (ATR) | 0.05 | 0.15 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 90.06 | 47.50 |
Castellum Inc is focused on building a successful technology services, solutions, and products company in the areas of cybersecurity, IT, electronic warfare, information warfare, system modernization, and information operations with businesses in the defense, federal, civilian, and commercial markets. Services include intelligence analysis, software development, software engineering, program management, strategic and mission planning, information assurance, cybersecurity and policy support, data analytics, and model-based systems engineering. The company maintains one operating and reportable segment, which is the delivery of products and services in the areas of information technology, electronic warfare, information warfare and cybersecurity in the governmental and commercial markets.
Cypherpunk Technologies Inc is a privacy technology company focused on implementing a digital asset treasury business anchored by Zcash, which is a cryptographic digital asset that operates on a decentralized, open-source blockchain network known as the Zcash Network. Through its subsidiary, the company is also engaged in developing novel therapies for patients with cancer. The group holds Zcash as part of its digital treasury business and has the following drug candidates under development in its biopharma business: Sirexatamab (DKN-01), a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1; and a preclinical antibody program, FL-501, that is designed to treat cachexia-related indications.